- Conditions
- Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
- Interventions
- PER977, Placebo
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 33,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Duarte, California • Tampa, Florida + 2 more
- Conditions
- Lymphoma
- Interventions
- Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Duarte, California • Stanford, California • Iowa City, Iowa + 6 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
- Interventions
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
- Conditions
- Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
- Interventions
- CBX129801, Placebo
- Drug
- Lead sponsor
- Cebix Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- Escondido, California • Tustin, California • Walnut Creek, California + 5 more
- Conditions
- Paralysis, Unilateral, Vocal Cord
- Interventions
- APrevent® VOIS-Implant
- Device
- Lead sponsor
- APrevent Biotech GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • Cleveland, Ohio + 1 more
- Conditions
- Crohn's Disease
- Interventions
- Etrasimod, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 192
- States / cities
- Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more
- Conditions
- Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
- Interventions
- Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
- Device
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 22 Years to 50 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Angioedema
- Interventions
- Placebo, Lanadelumab
- Other · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
- Conditions
- Tuberculosis
- Interventions
- Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
- Drug · Dietary Supplement
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Volunteers
- Interventions
- AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Sickle Cell Disease
- Interventions
- SelG1, Placebo
- Drug
- Lead sponsor
- Reprixys Pharmaceutical Corporation
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
- Conditions
- Reproductive Sterilization
- Interventions
- Adiana Transcervical Sterilization System
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2013
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Roseville, California • San Rafael, California + 11 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 937 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 39
- States / cities
- Cerritos, California • Escondido, California • Garden Grove, California + 31 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors
- Interventions
- Raludotatug deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Marietta, Georgia • Ann Arbor, Michigan • East Brunswick, New Jersey + 5 more
- Conditions
- Fibromyalgia
- Interventions
- placebo, AGN 203818
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- Postherpetic Neuralgia
- Interventions
- Retigabine, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Cilostazol 100 MG, Placebo
- Drug · Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Southfield, Michigan
- Conditions
- Melanoma
- Interventions
- MAGE-A3 ASCI injections without Poly IC:LC, MAGE-A3 ASCI injections with Poly IC:LC
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- VRC-HIVADV014-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Ischemic Stroke
- Interventions
- Enoxaparin sodium
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, PALB2 Gene Mutation, Ovarian Cancer
- Interventions
- Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
- Procedure
- Lead sponsor
- University Medical Center Nijmegen
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 8,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin
- Biological · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio